 The purpose of this protocol is 1. To comprehensively evaluate patients with autoinflammatory diseases clinically, genetically and immunologically at the autoinflammatory disease clinic at the NIH. 2. To follow patients with autoinflammatory Diseases that are genetically defined including Neonatal-Onset Multisystem Inflammatory Disease NOMID, the most severe clinical phenotype of Cryopyrin-Associated Periodic Syndromes CAPS, Deficiency of IL-1 Receptor Antagonist DIRA, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated temperatures CANDLE, and STING-Associated Vasculopathy with onset in Infancy SAVI, and those with genetically undefined autoinflammatory disorders to determine long-term disease outcomes. 3. To develop biomarkers that help us assess disease activity and response to treatment. 4. To assess the eligibility of affected patients for inclusion in ongoing and planned treatment protocols. 